Difelikefalin: A Novel Therapy for Dialysis Patient Care

Overview

Journal Kidney Med

Specialty Nephrology

Date 2022 Aug 22

PMID 35991692

Authors

Suzanne Watnick

Catherine R Butler

Affiliations

Soon will be listed here.

Citing Articles

Effect of Omega-3 Fatty Acid Supplementation in the Treatment of Uremic Pruritus among Dialytic Chronic Kidney Disease Patients: A Meta-analysis.

Borbe J, Elvambuena B, Eugenio F, Tan R Acta Med Philipp. 2024; 58(8):125-131.

PMID: 38812761 PMC: 11132289. DOI: 10.47895/amp.vi0.7015.

References

Chavkin C . The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology. 2010; 36(1):369-70. PMC: 3055513. DOI: 10.1038/npp.2010.137. View

Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K . Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med. 2022; 4(8):100513. PMC: 9418597. DOI: 10.1016/j.xkme.2022.100513. View

Albert-Vartanian A, Boyd M, Hall A, Morgado S, Nguyen E, Nguyen V . Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?. J Clin Pharm Ther. 2016; 41(4):371-82. DOI: 10.1111/jcpt.12404. View

Topf J, Wooldridge T, McCafferty K, Schomig M, Csiky B, Zwiech R . Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Med. 2022; 4(8):100512. PMC: 9396406. DOI: 10.1016/j.xkme.2022.100512. View

. Medicare Program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final Rule. Fed Regist. 2015; 80(215):68967-9077. View

Ledley F, McCoy S, Vaughan G, Cleary E . Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies. JAMA. 2020; 323(9):834-843. PMC: 7054843. DOI: 10.1001/jama.2020.0442. View

Kalantar-Zadeh K, Lockwood M, Rhee C, Tantisattamo E, Andreoli S, Balducci A . Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat Rev Nephrol. 2022; 18(3):185-198. DOI: 10.1038/s41581-021-00518-z. View

Roth B, Baner K, Westkaemper R, Siebert D, Rice K, Steinberg S . Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002; 99(18):11934-9. PMC: 129372. DOI: 10.1073/pnas.182234399. View

Butelman E, Kreek M . Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol. 2015; 6:190. PMC: 4561799. DOI: 10.3389/fphar.2015.00190. View

10.

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F . A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med. 2019; 382(3):222-232. DOI: 10.1056/NEJMoa1912770. View

11.

Flythe J, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E . Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study. Clin J Am Soc Nephrol. 2018; 13(5):735-745. PMC: 5969481. DOI: 10.2215/CJN.10850917. View

12.

Viecelli A, Tong A, OLone E, Ju A, Hanson C, Sautenet B . Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. Am J Kidney Dis. 2018; 71(5):690-700. DOI: 10.1053/j.ajkd.2017.12.003. View